Zobrazeno 1 - 10
of 1 211
pro vyhledávání: '"William G. Wierda"'
Autor:
Janani Ravikrishnan, Daisy Y. Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai, Shrilekha Misra, Charmelle D. Williams, John Sanchez, Andrew Mitchell, Suresh Satpati, Elizabeth Perry, Tierney Kaufman, Chaomei Liu, Arletta Lozanski, Gerard Lozanski, KerryA Rogers, Adam S. Kittai, Seema A. Bhat, Mary C. Collins, Matthew S. Davids, Nitin Jain, William G. Wierda, Rosa Lapalombella, John C. Byrd, Fenlai Tan, Yi Chen, Yu Chen, Yue Shen, Stephen P. Anthony, Jennifer A. Woyach, Deepa Sampath
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Patients with chronic lymphocytic leukemia (CLL) respond well to initial treatment with the Bcell lymphoma 2 (BCL2) inhibitor venetoclax. Upon relapse, they often retain sensitivity to BCL2 targeting, but durability of response remains a concern. We
Externí odkaz:
https://doaj.org/article/84739096159249b4b8f8ad48426936e4
Autor:
Panpan Liu, Kefeng Wang, Jianan Li, Marcia A. Ogasawara, Zhongjun Xia, William G. Wierda, Michael J. Keating, Yiqing Li, Peng Huang
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
It has been known for decades that the incidence of chronic lymphocytic leukemia (CLL) is significantly lower in Asia than in Western countries, but the reason responsible for this difference still remains a major knowledge gap. Using GeneChip® miRN
Externí odkaz:
https://doaj.org/article/7f2d42e2e1154ef885a7a0b0e3cca205
Autor:
Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady Tantawy, Samuel Clark Mcneely, Narasimha Marella, Kevin Ebata, Jennifer Woyach, Krish Patel, Constantine Tam, Toby Eyre, Chan Cheah, Nirav N Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Denise Wang, Anthony R. Mato, Varsha Gandhi, William G. Wierda
Publikováno v:
HemaSphere, Vol 7, p e6233246 (2023)
Externí odkaz:
https://doaj.org/article/961683113b1e4eb4ab33e8253c7c06f8
Autor:
Fadi Haddad, Elias Jabbour, Marianne Zoghbi, Nicholas Short, Jayastu Senapati, Walid Macaron, Cedric Nasnas, Lewis Nasr, Naveen Pemmaraju, Nitin Jain, William G. Wierda, Gautam Borthakur, Guillermo Montalban-Bravo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Kelly Chien, Jennifer Thankachan, Rebecca Garris, Hagop Kantarjian
Publikováno v:
HemaSphere, Vol 7, p e9487430 (2023)
Externí odkaz:
https://doaj.org/article/2b0e4d5a85a34a2aa5d33686e7ff1549
Autor:
Paolo Ghia, John Allan, Tanya Siddiqi, William G. Wierda, Constantine Tam, Carol Moreno, Alessandra Tedeschi, Edith Szafer-Glusman, Cathy Zhou, Chris Abbazio, Jim Dean, Anita Szoke, Paul M. Barr
Publikováno v:
HemaSphere, Vol 7, p e2822842 (2023)
Externí odkaz:
https://doaj.org/article/8d8716a5908d4a09b0fedb6fa9d0dbce
Autor:
Jan Burger, Ekaterina Kim, Mariela Sivina, Ghayas Issa, Philip Thompson, William G. Wierda, Alessandra Ferrajoli
Publikováno v:
HemaSphere, Vol 7, p e06532fc (2023)
Externí odkaz:
https://doaj.org/article/ce03dfa519c447a68d7c64a5cd703413
Autor:
Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Jinghui Dong, Sabina Adhikary, Lang Zhou, Petra C. Schuberth, Imi Faghmous, Behzad Kharabi Masouleh, Roch Houot
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-11 (2022)
Abstract Background Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study r
Externí odkaz:
https://doaj.org/article/c6f5581c75904c159d9b64a730068459
Autor:
Jeffrey P. Sharman, Juliana M. L. Biondo, Michelle Boyer, Kirsten Fischer, Michael Hallek, Dingfeng Jiang, Arnon P. Kater, Michele Porro Lurà, William G. Wierda
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 492-506 (2022)
Abstract We reviewed the literature (January 2010–June 2021) on the effectiveness of debulking strategies before venetoclax initiation in patients with chronic lymphocytic leukemia to reduce tumor burden, downgrade tumor lysis syndrome (TLS) risk,
Externí odkaz:
https://doaj.org/article/c433192b9d0e4a749e2f5783f5e3d713
Autor:
Burcu Aslan, Gorkem Kismali, Lakesla R. Iles, Ganiraju C. Manyam, Mary L. Ayres, Lisa S. Chen, Mihai Gagea, Maria Teresa Sabrina Bertilaccio, William G. Wierda, Varsha Gandhi
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 5, Pp 1-12 (2022)
Abstract Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton’s tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due to C481 kinase domain mutations. The clinical activity of pi
Externí odkaz:
https://doaj.org/article/8888c6f8f7de463288f684d22b1c67b9
Autor:
Rong Chen, Jennifer Tsai, Philip A. Thompson, Yuling Chen, Ping Xiong, Chaomei Liu, Francis Burrows, Mariela Sivina, Jan A. Burger, Michael J. Keating, William G. Wierda, William Plunkett
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-15 (2021)
Abstract The constitutive activation of B-cell receptor (BCR) signaling, together with the overexpression of the Bcl-2 family anti-apoptotic proteins, represents two hallmarks of chronic lymphocytic leukemia (CLL) that drive leukemia cell proliferati
Externí odkaz:
https://doaj.org/article/c1c1b56b91374e5199779633b84aeb68